DYN,EDIT Stock Price and Quote

Peers: ALMS ERAS KRYS KYMR TNGX CRNX RYTM APGE BMRN INCY

| Held by: VTI XBI IWM VXF VB VBR IBB IWN VTWO SCHA

Index	RUT
Market Cap	4.85B
Enterprise Value	4.19B
Income	-519.41M
Sales	0.00M
Book/sh	4.24
Cash/sh	4.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	258
IPO	Sep 17, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	6.13
P/C	5.40
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.02
Current Ratio	12.02
Debt/Eq	0.33
LT Debt/Eq	0.30
Option/Short	Yes / Yes

EPS (ttm)	-3.33
EPS next Y	-3.35
EPS next Q	-0.89
EPS this Y	-2.58%
EPS next Y	5.80%
EPS next 5Y	9.24%
EPS past 3/5Y	-2.41% 3.39%
Sales past 3/5Y	- -
EPS Y/Y TTM	13.71%
Sales Y/Y TTM	-
EPS Q/Q	-10.86%
Sales Q/Q	-
Earnings	Jul 29 AMC
EPS/Sales Surpr.	-44.23% -

Insider Own	19.47%
Insider Trans	-17.25%
Inst Own	85.19%
Inst Trans	4.00%
ROA	-60.29%
ROE	-81.57%
ROIC	-56.70%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.42%
SMA50	11.14%
SMA200	32.54%
Trades

Shs Outstand	165.67M
Shs Float	150.38M
Short Float	14.61%
Short Ratio	9.87
Short Interest	21.97M
52W High	27.31 -4.85%
52W Low	11.65 123.10%
Volatility	3.39% 4.59%
ATR (14)	1.15
RSI (14)	56.68
Beta	1.08
Rel Volume	0.67
Avg Volume	2.23M
Volume	1,484,373

Perf Week	0.08%
Perf Month	11.93%
Perf Quarter	47.95%
Perf Half Y	70.36%
Perf YTD	32.82%
Perf Year	117.04%
Perf 3Y	153.46%
Perf 5Y	61.47%
Perf 10Y	-
Recom	1.18
Target Price	39.40
Prev Close	26.78
Price	25.98
Change %	-2.99%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-26	Initiated	Cantor Fitzgerald	Overweight
Jun-26-26	Initiated	TD Cowen	Buy
Dec-10-25	Upgrade	Oppenheimer	Perform → Outperform	$40
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy	$35
Jun-24-25	Initiated	Bernstein	Mkt Perform	$13
Jun-11-25	Resumed	Raymond James	Outperform	$37
Jun-02-25	Resumed	Oppenheimer	Outperform	$34
May-29-25	Initiated	Evercore ISI	Outperform	$46
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Dec-13-24	Initiated	Robert W. Baird	Outperform	$46
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$45
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral	$43 → $35
May-21-24	Reiterated	Chardan Capital Markets	Buy	$31 → $42
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33

Show Previous Ratings

Today 04:05PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-29-26 04:30PM	Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-28-26 07:30AM	Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) (GlobeNewswire)
Jul-24-26 04:05PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-23-26 04:05PM	Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
08:29AM	Loading…
Jul-22-26 08:29AM	Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) (InvestorsHub)
Jul-21-26 10:46PM	Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock (GlobeNewswire)
08:06PM	Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock (Stocktwits)
04:46PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:04PM	SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space (Stocktwits)
Jul-20-26 10:29AM	Dyne Therapeutics Trades Sideways Over An FDA Hurdle. Is It Time To Take Profits? (Investor's Business Daily)
07:30AM	Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Jun-22-26 04:10PM	Dyne Therapeutics Appoints Barry Greene to Board of Directors (GlobeNewswire) +5.40%
Jun-18-26 04:05PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-17-26 07:30AM	Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. (GlobeNewswire) +6.25%
07:30AM	Loading…
Jun-03-26 07:30AM	Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
May-26-26 07:30AM	Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
May-20-26 05:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.30%
07:46AM	Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval (GlobeNewswire)
May-13-26 07:30AM	Dyne Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-11-26 07:55AM	Dyne Therapeutics Q1 Net Loss Widens (RTT News)
07:30AM	Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-27-26 04:34PM	Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE Platform at 2026 ASGCT Annual Meeting (GlobeNewswire)
Apr-23-26 04:05PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-26 07:30AM	Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines (GlobeNewswire)
Mar-10-26 09:47PM	Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade (Insider Monkey) +11.81%
Mar-08-26 06:01PM	Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
06:00PM	Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Mar-02-26 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-26-26 05:52AM	Sarepta CEO To Jump Ship After 'Tumultuous' Year (Benzinga)
07:30AM	Loading…
Feb-25-26 07:30AM	Dyne Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-22-26 04:00PM	Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference (GlobeNewswire)
Feb-18-26 07:38PM	Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan (Insider Monkey)
Feb-16-26 12:23PM	Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry (Insider Monkey)
Jan-27-26 09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-20-26 07:30AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-15-26 11:35AM	Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) (Insider Monkey) -5.90%
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-07-26 07:30AM	Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.01%
Dec-23-25 07:30AM	Dyne Therapeutics Appoints Vikram Karnani to Board of Directors (GlobeNewswire)
Dec-22-25 06:50AM	Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) (Insider Monkey)
Dec-11-25 04:05PM	Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
07:44AM	Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial (Insider Monkey)
Dec-10-25 06:20PM	Why Dyne Therapeutics Stock Was a Big Winner on Wednesday (Motley Fool) +6.78%
09:40AM	Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls (The Fly)
Dec-09-25 09:42PM	Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock (GlobeNewswire) -16.94%
06:42PM	Why Dyne Therapeutics Stock Tanked on Tuesday (Motley Fool)
04:54PM	Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More (Motley Fool)
02:22PM	Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate (Insider Monkey)
01:34PM	Dyne to seek accelerated approval of DMD drug on Phase I/II data (Clinical Trials Arena)
Dec-08-25 04:02PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +9.47%
03:07PM	Why Dyne Therapeutics Stock Was Blasting Higher Today (Motley Fool)
06:30AM	Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-07-25 11:00AM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET (GlobeNewswire)
Nov-30-25 12:26AM	Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release (Insider Monkey)
Nov-21-25 03:43PM	Why Dyne Therapeutics Stock Was Crushing it This Week (Motley Fool) +5.27%
Nov-05-25 04:10PM	Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -12.89%
Nov-03-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +6.78%
Oct-28-25 05:24AM	Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger (Insider Monkey)
Oct-27-25 06:17PM	Why Dyne Therapeutics Stock Crushed the Market on Monday (Motley Fool) +41.18%
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
Oct-16-25 04:33PM	Dyne's Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year (Insider Monkey)
Oct-06-25 06:01PM	Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +10.28%
Oct-04-25 04:54PM	Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data (Insider Monkey)
Oct-02-25 04:05PM	Dyne Therapeutics Appoints Brian Posner to its Board of Directors (GlobeNewswire)
Sep-29-25 08:35AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire) -5.93%
Sep-10-25 12:20AM	Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating (Insider Monkey)
Aug-27-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:13AM	Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT (Insider Monkey)
Aug-17-25 11:41PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy (Insider Monkey)
Aug-06-25 12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com) +10.70%
Aug-04-25 07:30AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Jul-31-25 09:55AM	Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? (Zacks)
Jul-28-25 04:10PM	Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -6.43%
Jul-16-25 07:00AM	Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer (Business Wire) +12.68%
Jul-11-25 11:27AM	RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT (Insider Monkey)
Jul-02-25 04:01PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Jun-30-25 09:45PM	Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock (GlobeNewswire) -8.82%
04:05PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital (GlobeNewswire)
Jun-24-25 12:46PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101 (Insider Monkey)
Jun-18-25 09:45AM	Dyne at attractive entry point following pullback, says Chardan (TipRanks)
Jun-17-25 07:00AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting (GlobeNewswire) -21.42%
Jun-16-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET (GlobeNewswire)
Jun-05-25 07:30AM	Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress (GlobeNewswire)
May-08-25 07:30AM	Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +20.16%
Apr-25-25 05:05AM	EC grants orphan drug designation to Dyne Therapeutics DMD therapy (Pharmaceutical Technology)
Apr-24-25 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +14.20% +6.22%
Apr-15-25 07:30AM	Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments (GlobeNewswire) +5.09%
Apr-14-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.11%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -11.76%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer (GlobeNewswire)
04:19PM	Dyne Therapeutics appoints Erick Lucera as CFO (SeekingAlpha)

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

CEOMr. John G. Cox M.B.A.

CPAMr. Erick J. Lucera C.F.A.

Chief Innovation OfficerDr. Oxana Beskrovnaya Ph.D.

Chief Commercial OfficerMs. Johanna Friedl-Naderer

M.D.Dr. Douglas Kerr M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rhodes Jason P	Director	Aug 14 '26	Sale	25.00	2,160,516	54,012,900	428,946	Aug 17 05:30 PM
Rhodes Jason P	Director	Aug 13 '26	Sale	26.20	426,412	11,171,994	751,411	Aug 17 05:30 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Aug 13 '26	Sale	26.28	226	5,939	153,982	Aug 17 04:08 PM
Kerr Douglas	Chief Medical Officer	Aug 13 '26	Sale	26.28	1,556	40,892	167,599	Aug 17 04:08 PM
Cox John	CEO & President	Aug 13 '26	Sale	26.28	4,986	131,032	363,165	Aug 17 04:07 PM
Lucera Erick	Chief Financial Officer	Aug 13 '26	Sale	26.28	1,797	47,225	119,766	Aug 17 04:06 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 14 '26	Proposed Sale	25.96	322,465	8,371,191		Aug 14 05:47 PM
Atlas Venture Fund XI, LP	Shareholder	Aug 14 '26	Proposed Sale	25.96	1,359,674	35,297,137		Aug 14 05:47 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 14 '26	Proposed Sale	25.96	478,377	12,418,667		Aug 14 05:46 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 13 '26	Proposed Sale	26.17	94,415	2,470,841		Aug 13 05:36 PM
Atlas Venture Fund XI, LP	Shareholder	Aug 13 '26	Proposed Sale	26.17	268,354	7,022,824		Aug 13 05:36 PM
Atlas Venture Opportunity Fund	Shareholder	Aug 13 '26	Proposed Sale	26.17	63,643	1,665,537		Aug 13 05:36 PM
Cox John	Officer	Aug 13 '26	Proposed Sale	26.28	4,986	131,034		Aug 13 05:04 PM
Lucera Erick	Officer	Aug 13 '26	Proposed Sale	26.28	1,797	47,226		Aug 13 05:03 PM
Kerr Douglas	Officer	Aug 13 '26	Proposed Sale	26.28	2,443	64,203		Aug 13 05:03 PM
Kersten Dirk	Director	Jul 27 '26	Sale	25.51	261,460	6,670,769	3,586,796	Jul 29 04:15 PM
ForDyne B.V.	Affiliate	Jul 27 '26	Proposed Sale	25.51	261,460	6,670,760		Jul 27 04:19 PM
Rhodes Jason P	Director	Jul 06 '26	Sale	22.79	480,240	10,944,670	875,912	Jul 08 05:35 PM
Rhodes Jason P	Director	Jul 07 '26	Sale	23.26	297,211	6,913,822	2,962	Jul 08 05:35 PM
ATLAS VENTURE ASSOCIATES XI, L	Shareholder	Jul 07 '26	Proposed Sale	22.84	5,000	114,200		Jul 07 05:06 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 07 '26	Proposed Sale	22.84	60,858	1,389,997		Jul 07 05:06 PM
Atlas Venture Fund XI, LP	Shareholder	Jul 07 '26	Proposed Sale	22.84	153,966	3,516,583		Jul 07 05:05 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 07 '26	Proposed Sale	22.84	77,387	1,767,519		Jul 07 05:05 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 06 '26	Proposed Sale	23.07	100,019	2,307,438		Jul 06 05:17 PM
Atlas Venture Fund XI, LP	Shareholder	Jul 06 '26	Proposed Sale	23.07	253,039	5,837,610		Jul 06 05:17 PM
Atlas Venture Opportunity Fund	Shareholder	Jul 06 '26	Proposed Sale	23.07	127,182	2,934,089		Jul 06 05:17 PM
Rhodes Jason P	Director	Jun 26 '26	Sale	21.28	309,268	6,581,223	1,016,633	Jun 30 07:05 PM
Rhodes Jason P	Director	Jun 29 '26	Sale	21.14	195,427	4,131,327	975,931	Jun 30 07:05 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 29 '26	Proposed Sale	20.94	51,756	1,083,771		Jun 29 05:50 PM
Atlas Venture Fund XI, LP	Shareholder	Jun 29 '26	Proposed Sale	20.94	102,969	2,156,171		Jun 29 05:50 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 29 '26	Proposed Sale	20.94	40,702	852,300		Jun 29 05:49 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 26 '26	Proposed Sale	20.61	81,903	1,688,021		Jun 26 05:04 PM
Atlas Venture Fund XI, LP	Shareholder	Jun 26 '26	Proposed Sale	20.61	162,954	3,358,482		Jun 26 05:04 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 26 '26	Proposed Sale	20.61	64,411	1,327,511		Jun 26 05:04 PM
Lucera Erick	Chief Financial Officer	Jun 25 '26	Sale	20.37	2,362	48,114	121,563	Jun 26 04:15 PM
Rhodes Jason P	Director	Jun 23 '26	Sale	21.13	147,760	3,122,169	1,106,036	Jun 26 08:40 AM
Rhodes Jason P	Director	Jun 24 '26	Sale	21.02	95,900	2,015,818	1,086,063	Jun 26 08:40 AM
Rhodes Jason P	Director	Jun 25 '26	Sale	21.10	24,100	508,510	1,081,044	Jun 26 08:40 AM
Atlas Venture Opportunity Fund	Shareholder	Jun 25 '26	Proposed Sale	20.33	6,382	129,746		Jun 25 05:29 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 25 '26	Proposed Sale	20.33	5,019	102,036		Jun 25 05:29 PM
Atlas Venture Fund XI, LP	Shareholder	Jun 25 '26	Proposed Sale	20.33	12,699	258,171		Jun 25 05:28 PM
Lucera Erick	Officer	Jun 25 '26	Proposed Sale	20.37	2,362	48,103		Jun 25 05:11 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 24 '26	Proposed Sale	20.26	25,397	514,543		Jun 24 05:36 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 24 '26	Proposed Sale	20.26	19,973	404,653		Jun 24 05:33 PM
Atlas Venture Fund XI, LP	Shareholder	Jun 24 '26	Proposed Sale	20.26	50,530	1,023,738		Jun 24 05:32 PM
Kersten Dirk	Director	Jun 22 '26	Sale	20.57	190,676	3,922,263	3,921,542	Jun 24 04:27 PM
Kersten Dirk	Director	Jun 23 '26	Sale	21.05	73,286	1,542,349	3,848,256	Jun 24 04:27 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 23 '26	Proposed Sale	20.87	30,774	642,253		Jun 23 06:26 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 23 '26	Proposed Sale	20.87	39,131	816,664		Jun 23 06:25 PM
Atlas Venture Fund XI, LP	Shareholder	Jun 22 '26	Proposed Sale	20.87	77,855	1,624,834		Jun 23 06:19 PM
Kersten Dirk	Director	Jun 18 '26	Sale	20.07	46,901	941,373	4,112,218	Jun 22 04:15 PM
Kersten Dirk	Director	Jun 17 '26	Sale	20.14	37,454	754,316	4,159,119	Jun 22 04:15 PM
Kerr Douglas	Chief Medical Officer	Jun 16 '26	Sale	18.33	887	16,259	169,155	Jun 17 04:08 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Jun 16 '26	Sale	18.33	145	2,658	154,208	Jun 17 04:07 PM
Cox John	CEO & President	Jun 16 '26	Sale	18.33	2,683	49,179	368,151	Jun 17 04:07 PM
ForDyne B.V.	Affiliate	Jun 17 '26	Proposed Sale	18.33	348,317	6,384,651		Jun 17 04:03 PM
Cox John	Officer	Jun 16 '26	Proposed Sale	18.33	2,683	49,191		Jun 16 04:10 PM
Posner Brian S	Director	Jun 08 '26	Buy	16.94	2,000	33,880	24,500	Jun 09 05:06 PM
Posner Brian S	Director	Jun 03 '26	Buy	17.48	2,500	43,700	22,500	Jun 05 04:10 PM
Posner Brian S	Director	May 26 '26	Buy	18.21	2,000	36,420	20,000	May 28 04:11 PM
Posner Brian S	Director	May 20 '26	Buy	17.12	2,500	42,800	18,000	May 22 04:10 PM
Friedl-Naderer Johanna	Chief Commercial Officer	May 13 '26	Sale	18.36	228	4,186	154,353	May 14 04:05 PM
Kerr Douglas	Chief Medical Officer	May 13 '26	Sale	18.36	1,564	28,715	170,042	May 14 04:04 PM
Lucera Erick	Chief Financial Officer	May 13 '26	Sale	18.36	1,448	26,585	123,925	May 14 04:03 PM
Cox John	CEO & President	May 13 '26	Sale	18.36	3,311	60,790	370,834	May 14 04:02 PM
Cox John	Officer	May 13 '26	Proposed Sale	18.36	3,311	60,805		May 13 04:57 PM
Lucera Erick	Officer	May 13 '26	Proposed Sale	18.36	1,448	26,592		May 13 04:55 PM
Rhodes Jason P	Director	May 06 '26	Sale	18.18	83,219	1,512,921	7,962	May 06 05:09 PM
Rhodes Jason P	Director	May 04 '26	Sale	18.00	11,904	214,272	8,450	May 06 05:09 PM
Rhodes Jason P	Director	May 05 '26	Sale	18.03	11,600	209,148	8,390	May 06 05:09 PM
Atlas Venture Fund XI, LP	Shareholder	May 06 '26	Proposed Sale	17.47	43,621	762,059		May 06 04:43 PM
Atlas Venture Opportunity Fund	Shareholder	May 06 '26	Proposed Sale	17.47	21,926	383,047		May 06 04:43 PM
Atlas Venture Associates XI, L	Shareholder	May 06 '26	Proposed Sale	17.47	428	7,477		May 06 04:42 PM
Atlas Venture Opportunity Fund	Shareholder	May 06 '26	Proposed Sale	17.47	17,244	301,253		May 06 04:42 PM
Atlas Venture Fund XI, LP	Shareholder	May 05 '26	Proposed Sale	17.71	6,081	107,695		May 05 04:39 PM
Atlas Venture Opportunity Fund	Shareholder	May 05 '26	Proposed Sale	17.71	3,056	54,122		May 05 04:37 PM
Atlas Venture Associates XI, L	Shareholder	May 05 '26	Proposed Sale	17.71	60	1,063		May 05 04:36 PM
Atlas Venture Opportunity Fund	Shareholder	May 05 '26	Proposed Sale	17.71	2,403	42,557		May 05 04:36 PM
Atlas Venture Opportunity Fund	Shareholder	May 04 '26	Proposed Sale	17.39	2,466	42,884		May 04 05:00 PM
Atlas Venture Fund XI, LP	Shareholder	May 04 '26	Proposed Sale	17.39	6,241	108,531		May 04 04:59 PM
Atlas Venture Opportunity Fund	Shareholder	May 04 '26	Proposed Sale	17.39	3,136	54,535		May 04 04:59 PM
Atlas Venture Associates XI, L	Shareholder	Apr 29 '26	Proposed Sale	17.39	61	1,061		May 04 04:59 PM
Rhodes Jason P	Director	Apr 28 '26	Sale	18.38	227,337	4,178,516	8,511	Apr 30 05:22 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 28 '26	Proposed Sale	18.04	47,103	849,738		Apr 28 04:44 PM
Atlas Venture Fund XI, LP	Shareholder	Apr 28 '26	Proposed Sale	18.04	119,167	2,149,773		Apr 28 04:43 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 28 '26	Proposed Sale	18.04	59,836	1,079,441		Apr 28 04:43 PM
Atlas Venture Associates XI, L	Shareholder	Apr 28 '26	Proposed Sale	18.04	1,171	21,125		Apr 28 04:42 PM
Rhodes Jason P	Director	Apr 27 '26	Sale	18.15	173,493	3,148,898	9,682	Apr 27 06:15 PM
Rhodes Jason P	Director	Apr 24 '26	Sale	18.48	137,948	2,549,279	10,576	Apr 27 06:15 PM
Rhodes Jason P	Director	Apr 23 '26	Sale	19.19	73,108	1,402,943	11,286	Apr 27 06:15 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 27 '26	Proposed Sale	18.26	45,709	834,646		Apr 27 04:49 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 27 '26	Proposed Sale	18.26	35,947	656,392		Apr 27 04:48 PM
Atlas Venture Fund XI, LP	Shareholder	Apr 27 '26	Proposed Sale	18.26	90,943	1,660,619		Apr 27 04:48 PM
Atlas Venture Associates XI, L	Shareholder	Apr 27 '26	Proposed Sale	18.26	894	16,324		Apr 27 04:48 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 24 '26	Proposed Sale	18.90	28,583	540,219		Apr 24 04:47 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 24 '26	Proposed Sale	18.90	36,345	686,920		Apr 24 04:46 PM
Atlas Venture Fund XI, LP	Shareholder	Apr 24 '26	Proposed Sale	18.90	72,310	1,366,659		Apr 24 04:46 PM
Atlas Venture Associates XI, L	Shareholder	Apr 24 '26	Proposed Sale	18.90	710	13,419		Apr 24 04:45 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 23 '26	Proposed Sale	19.67	15,148	297,961		Apr 23 04:46 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 23 '26	Proposed Sale	19.67	19,261	378,864		Apr 23 04:45 PM

DYN

Dyne Therapeutics Inc

EDIT

Editas Medicine Inc

DYN

Dyne Therapeutics Inc

EDIT

Editas Medicine Inc

Upgrade your Finviz experience